Drugs /

amg 562

Back to Drugs List

Overview

NCI Definition [1]:
A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 BiTE antibody AMG 562 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD19 antigen expressed on malignant B-cells. This activates and redirects CTLs to CD19-expressing tumor cells, resulting in CTL-mediated killing of tumor cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages

Clinical Trials

View Clinical Trials for amg 562

Amg 562 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating amg 562, 1 is phase 1 (1 open).

BCL2 Fusion, BCL6 Fusion, and MYC Fusion are the most frequent biomarker inclusion criteria for amg 562 clinical trials.

Diffuse large B-cell lymphoma, double-hit lymphoma, and follicular lymphoma are the most common diseases being investigated in amg 562 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Amg 562
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating amg 562 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bite antibody amg 562, cd19/cd3-directed bispecific t-cell engager antibody amg 562, bispecific t-cell engager antibody amg 562, anti-cd19/cd3 bite antibody amg 562, amg562, amg-562
Drug Target(s) [2]:
CD19, CD3G
NCIT ID [1]:
C153215

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.